MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2023 International Congress

    Safety and efficacy of P2B001 (low dose combination of extended-release pramipexole and rasagiline) in patients with early Parkinson’s disease: Subgroup analyses from a randomized, controlled trial

    D. Falconer, P. Litman, H. Friedman, S. Oren, C. Fitter-Attas (Alexandria, USA)

    Objective: Evaluate the efficacy and safety of P2B001 for different subgroups of patients with early Parkinson’s disease (PD). Background: P2B001 is an investigational, fixed low-dose,…
  • 2023 International Congress

    Why is HAL effective in improving gait and balance function in Parkinson’s disease?

    N. Togashi, K. Tateno, Y. Kondo, M. Masanobu, A. Kawanami, K. Hasegawa (Sagamihara, Japan)

    Objective: We performed rehabilitation using a Hybrid Assisted Limb (HAL) for PD and found that gait and balance functions improved before and after HAL rehabilitation.…
  • 2023 International Congress

    Fecal tyrosine decarboxylase and motor response complications in Parkinson’s Disease

    JW. Hor, SY. Lim, TS. Toh, CW. Chong, CSJ. Teh, SL. Song, KY. Khaw, AH. Tan (Kuala Lumpur, Malaysia)

    Objective: To investigate the clinical correlates of gut microbe-derived tyrosine decarboxylase (tdc) and motor dysfunction in Parkinson’s Disease (PD) patients. Background: Gut microbe-derived tdc was…
  • 2023 International Congress

    The role of the glymphatic system on the severity and distribution of alpha-synuclein pathology in alpha-synuclein fibril induced rat model of Parkinson’s disease

    E. Gök Dursun, M. Karataş, M. çetinkaya, K. Karlı Oğuz, B. Tel, G. Yalçın çakmaklı, B. Elibol (Ankara, Turkey)

    Objective: The aim of this study is to investigate the contribution of the glymphatic system to the pathophysiology of Parkinson's disease (PD). Background: Neurotoxicity of…
  • 2023 International Congress

    Clozapine Therapy for Parkinson’s Disease Psychosis: A 21-Year Service Analysis

    W. Woods, T. Payne, N. Hoyle, O. Bandmann (Sheffield, United Kingdom)

    Objective: To review the demographic aspects, safety, and efficacy of Clozapine treatment for Parkinson’s Disease Psychosis (PDP) in a large patient cohort. Background: The impact…
  • 2023 International Congress

    The East London Parkinson Disease Project – preliminary results from a diverse population

    A. Zirra, KC. Dey, E. Camboe, T. Haque, A. Ben-Joseph, J. Kahan, D. Gallagher, C. Budu, B. Huxford, C. Simonet, A. Lees, CR. Marshall, AJ. Noyce (London, United Kingdom)

    Objective: The East London Parkinson Disease (ELPD) project is a platform study to understand the manifestations and determinants of PD in a diverse population. Background:…
  • 2023 International Congress

    Effects of NE3107 anti-inflammatory treatment on motor activity and neurodegenerative features of Parkinson’s disease in a marmoset monkey model

    I. Philippens, C. Ahlem, C. Reading (Antwerp, Belgium)

    Objective: To demonstrate the effects of an oral, anti-inflammatory agent, NE3107, on motor activity, levodopa-induced dyskinesia (LID) induction, and neuron survival in a marmoset model…
  • 2023 International Congress

    Clinical progression in males and females with early treatment-naive Parkinson’s disease

    T. Kassuba, B. Ribba, T. Simuni, K. Marek, A. Siderowf, L. Chahine, M. Picillo, P. Brundin, G. Pagano (Basel, Switzerland)

    Objective: To investigate differences in the progression of motor and non-motor symptoms and striatal degeneration between males and females with Parkinson’s disease (PD). Background: Biological…
  • 2023 International Congress

    STRAT-PARK: a biomarker and stratification initiative for Parkinson’s disease

    K. Stige, S. Kverneng, S. Sharma, GO. Skeie, E. Sheard, M. Søgnen, S. Af Geijerstam, T. Vetås, C. Dölle, F. Dick, A. Wahlvåg, E. Berntsen, F. Riemer, P. Goa, K. Haugarvoll, S. Buch, D. Reese, D. Babiker, Y. Mahdi, T. Wade, G. Miranda, J. Ganguly, Y. Tamilselvam, J. Chai, S. Bansal, D. Aur, M. Haacke, M. Jog, C. Tzoulis (Trondheim, Norway)

    Objective: The STRAT-PARK initiative aims to stratify Parkinson’s disease (PD) according to underlying molecular mechanisms, and to develop clinically applicable biomarkers for patient stratification. Background:…
  • 2023 International Congress

    Navigating Open Science in Canada with the Canadian Open Parkinson Network

    M. Cressatti, C. Normandeau, C. Degroot, I. Kathol, A. Stoessl, M. Mckeown, J. Miyasaki, R. Camicioli, D. Grimes, L. Kalia, A. Strafella, P. Macdonald, N. Dupré, E. Fon, O. Monchi (Calgary, Canada)

    Objective: The Canadian Open Parkinson Network (C-OPN) is a pan-Canadian initiative that bridges people, data and resources to accelerate new discoveries in the field of…
  • « Previous Page
  • 1
  • …
  • 114
  • 115
  • 116
  • 117
  • 118
  • …
  • 338
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
      • Welcome to the MDS Abstracts Site
      • Effect of marijuana on Essential Tremor: A case report
      • Advanced Search
      • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
      • Covid vaccine induced parkinsonism and cognitive dysfunction
      • Help & Support
      • About Us
      • Cookies & Privacy
      • Wiley Job Network
      • Terms & Conditions
      • Advertisers & Agents
      Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
      Wiley